EGFR and neoplasm: Importantly and in agreement with patient survival data (Fig 6B), xenografts from EGFR and c‐Fos double‐positive 143b cells were more aggressive, resulting in significantly shorter median survival and twofold to threefold increased tumor progression as compared to LM7‐derived tumors (Yuan et al, 2009; Ren et al, 2015b).